数量	カタログ番号	注文内容	Qty/Pk	価格
			96-Well Plate

数量	カタログ番号	注文内容	Qty/Pk	価格
	48-602MAG	Buffer Detection Kit for Magnetic Beads	1 Kit

528205 Sigma-AldrichPlasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem

The Plasminogen Activator Inhibitor-1, Human, Recombinant controls the biological activity of Plasminogen Activator. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

(M)SDS
試験成績書（CoA）
参考資料
Data Sheet

同義語: PAI-1

Primary Target: Tissue plasminogen activator (tPA) and urokinase (uPA)

View This Product on Sigma-Aldrich

お勧めの製品

概要

Replacement Information

価格＆在庫状況

カタログ番号	在庫状況	包装	Qty/Pk	価格	数量
528205-50UGCN	在庫状況検索中… — 現在国内在庫なし現在国内在庫有り販売中止在庫僅少現在国内在庫あり在庫を照会するにはログインしてください現在国内在庫有り現在国内在庫なし現在国内在庫有り Remaining : Will advise Remaining : Will advise 注文対象外お問合せください Contact Customer Service お問合せくださいお問合せください	樹脂ｱﾝﾌﾟﾙ	50 μg	価格を検索中… 価格が見つかりません Minimum Quantity needs to be mulitiple of Maximum Quantity is 弊社照会詳細を表示　値引 () — 弊社照会納入価格を閲覧するにはログインしてください	在庫状況を照会 —	お気に入り/ショッピングリストに追加お気に入り/ショッピングリストに追加お気に入りに追加されました

Description
Overview	PAI-1 is the primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified of latent material. PAI-1 is a marker for acute myocardial infarction and several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Reported to be an important prognostic factor in breast cancer patients. PAI-1 is highly stable when stored at or below pH 6.6.
Catalogue Number	528205
Brand Family	Calbiochem®
Synonyms	PAI-1

References
References	Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995. Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272. Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195. Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713. Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307. Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523. Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673. Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.

References

Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.

Product Information
ATP Competitive	N
Form	Liquid
Formulation	In 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
Reversible	N
Quality Level	MQ100

Applications

Biological Information
Primary Target	Tissue plasminogen activator (tPA) and urokinase (uPA)
Purity	≥95% by SDS-PAGE

Physicochemical Information
Cell permeable	N

Dimensions

Materials Information

Toxicological Information

Safety Information according to GHS

Safety Information

Product Usage Statements

Storage and Shipping Information
Ship Code	Dry Ice Only
Toxicity	Standard Handling
Storage	≤ -70°C
Avoid freeze/thaw	Avoid freeze/thaw
Do not freeze	Ok to freeze
Special Instructions	Following initial thaw, aliquot and freeze (-70°C).

Packaging Information

Transport Information

Supplemental Information

Specifications

Global Trade Item Number
カタログ番号	GTIN
528205-50UGCN	04055977196481

Documentation

Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem (M)SDS

タイトル
英語版製品安全データシート（(M)SDS）

Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem 試験成績書（CoA）

タイトル	ロット番号
528205	ロット番号を入力

参考資料

参考資料の概要
Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995. Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272. Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195. Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713. Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307. Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523. Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673. Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.

参考資料の概要

データシート

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision	24-August-2023 JSW
Synonyms	PAI-1
Description	Primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 is synthesized by vascular epithelium and hepatocytes. Used as a marker for acute myocardial infarction and in the diagnosis of several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Shown to have a role complimentary to that of α₂-anti-plasmin. Elevated levels are found in subjects with accelerated coronary artery disease. PP1 activity may limit the extent of metastasis, since uPA activity is a major contributory factor promoting dissolution of tumor matrix and basement membrane. May serve as an independent and strong prognosticator in breast cancer patients. Patients having elevated levels of PAI-1 in their primary tumors are more prone to relapse. Can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified free of the inactive material.
Form	Liquid
Formulation	In 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
Purity	≥95% by SDS-PAGE
Storage	Avoid freeze/thaw ≤ -70°C
Do Not Freeze	Ok to freeze
Special Instructions	Following initial thaw, aliquot and freeze (-70°C).
Toxicity	Standard Handling
References	Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995. Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272. Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195. Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713. Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307. Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523. Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673. Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.

カテゴリー

Life Science Research > Inhibitors and Biochemicals > Small Molecules & Inhibitors > Proteases Inhibitors > Plasminogen Activator Inhibitors

製品がカートに追加されました